Dachaigh › Leukemia myeloid geur › Pennsylvania
Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Pennsylvania
Tha 45 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann an Pennsylvania.
Bailtean ann an Pennsylvania
- Philadelphia34 sgrùdaidhean
- Pittsburgh18 sgrùdaidhean
- Harrisburg8 sgrùdaidhean
- Allentown8 sgrùdaidhean
- Scranton6 sgrùdaidhean
- Reading5 sgrùdaidhean
Teacsa sgrùdaidh oifigeil (Beurla)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Thomas Jefferson University Hospital, Philadelphia
A’ fastadhÌre 2
Aoisean 60 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07437950Assessment of Geriatric Evaluations Impact on New AML Guidance
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
A’ fastadhSgrùdadh amharc
Aoisean 50 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05909501Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- agus 7 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
A’ fastadhSgrùdadh amharc
Aoisean 0 gu 38 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- agus 4 a bharrachd
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- agus 6 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A’ fastadhÌre 1
Suas gu aois 21 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- agus 4 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Geisinger Medical Center, Danville
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- agus 1 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- agus 6 a bharrachd
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- agus 3 a bharrachd
A’ fastadhÌre 3
6 Months – 21 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
A’ fastadhÌre 1/2
30 Days · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Spoknwrd Clinical Trials Inc., Easton
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT06824168A Study of BGB-11417 in Participants With Myeloid Malignancies
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT04771130Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- UPENN Perelman Center for Advanced Medicine, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06846606Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Geisinger Medical Center, Danville
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A’ fastadhÌre 3
Aoisean 1 gu 25 · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07022678A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Cancer Care Associates of York, York
A’ fastadhSgrùdadh amharc
Aoisean 0 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Pittsburgh PA-PITT, Pittsburgh
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Pittsburgh PA-PITT, Pittsburgh
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT07223814The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- agus 3 a bharrachd
A’ fastadhÌre 1/2
Suas gu aois 22 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Children's Hospital of Philadelphia, Philadelphia
A’ fastadhÌre 3
29 Days – 21 Years · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Pennsylvania, Philadelphia
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT07007312Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT07565220Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- UPMC Hillman Cancer Center, Pittsburgh
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT06529731L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
A’ fastadhÌre 2/3
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 5 Lùna 2026 · NCT06788756Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
A’ fastadhÌre 1
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 3 Lùna 2026 · NCT06177067Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Penn Medicine Abramson Cancer Center, Philadelphia
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Iuch 2026 · NCT05442216CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Iuch 2026 · NCT05945849CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
A’ fastadh
Suas gu aois 25 · Gach gnè · Air ùrachadh 8 Iuch 2026 · NCT03810196CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
A’ fastadhÌre 1
Aoisean 0 gu 29 · Gach gnè · Air ùrachadh 7 Iuch 2026 · NCT07464951A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- agus 3 a bharrachd
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Ògmh 2026 · NCT04068597SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Cèit 2026 · NCT06222580Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Pennsylvania State University Hershey Medical Center, Hershey
A’ fastadhÌre 1
Suas gu aois 21 · Gach gnè · Air ùrachadh 22 Gibl 2026 · NCT05101551Massage Impact on Sleep in Pediatric Oncology
- Children's Hospital of Philadelphia, Philadelphia
A’ fastadh
Aoisean 12 gu 21 · Gach gnè · Air ùrachadh 15 Gibl 2026 · NCT06892158A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- Allegheny Health Network, Pittsburgh
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 24 Màrt 2026 · NCT04988555Phase IB/II of CPX-351 for Relapse Prevention in AML
- University of Pennsylvania, Philadelphia
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Màrt 2026 · NCT04990102A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Thomas Jefferson University Hospital, Philadelphia
A’ fastadhÌre 1
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 16 Màrt 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hospital of the University of Pennsylvania, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT05735184Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.